摘要
目的 探讨对晚期卵巢癌患者施行盆腔淋巴结清除术的临床意义。方法 对 86例晚期卵巢癌患者施行手术治疗 ,根据术后残留病灶的大小及是否行盆腔淋巴结清除术分成 3组 ,A组 :42例 ,行盆腔淋巴结清除术且残留病灶直径 <2cm ;B组 :2 6例 ,行盆腔淋巴结清除术但残留灶直径≥ 2cm ;C组 :18例未行盆腔淋巴结清除术且残留病灶≥ 2cm。 3组术后均行CAP方案化疗 6～ 8疗程 ,3组的临床分期及病理分级基本相同。结果 A组 5年生存率 30 .1% (13/42 ) ,B组 5年生存率 11.5 % (3/2 6 ) ,与A组比较差异显著 (P <0 .0 5 )。C组 5年生存率 11.1% (2 /18) ,与B组比较差异无显著性 (P >0 .0 5 ) ,与A组比较差异显著 (P <0 .0 1)。结论 术中残留病灶直径 <2cm时同时行盆腔淋巴结清除术可明显提高患者生存率。如残留病灶≥
Objective To investigate the clinical significance of pelvic lymphadenectomy in advanced ovarian carcinoma. Methods A total of 86 cases of advanced ovarian cancer with surgical treatment were assigned to 3 groups according to the size of residual focus and the performance of pelvic lymphadenectomy. Group A consisted of 42 cases with pelvic lymphadenectomy and the diameter of residual focus smaller than 2 cm; Group B, 26 cases, underwent pelvic lymphadenectomy but with the residual focus larger than 2 cm; Group C consisted of 18 cases without pelvic lymphadenectomy and the diameter of residual focus larger than 2 cm. All patients received CAP chemotherapy for 6 to 8 course of treatment and were in similar clinical stages and pathological grading. Results The 5 year survival rate was 30.1% (13/42) in Group A, and 11.5% (3/26) in Group B with significant difference ( P <0.05). Group C's 5 year survival rate was 11.1%(2/18). No significant difference was found between Group B and C. Conclusion Application of pelvic lymphadenectomy on those with residual focus less than 2 cm can apparently improve the patients' survival rate. But when the diameter of the focus is larger than 2 cm, pelvic lymphadenectomy is not necessary.
出处
《第三军医大学学报》
CAS
CSCD
北大核心
2001年第5期586-587,共2页
Journal of Third Military Medical University
